1. TG Therapeutics will participate in the TD Cowen Summit. 2. Michael S. Weiss to speak on November 12, 2025. 3. The event will be live-streamed for investors. 4. TGTX focuses on treatments for B-cell diseases. 5. BRIUMVI approved by the FDA for multiple sclerosis treatment.
Participation in industry summits can positively influence investor perception and confidence, similar to past events that led to stock appreciation for biotech companies through increased visibility and potential partnerships or investor interest.
Communication of advancements and strategic direction, highlighted in events like this, can encourage confidence among investors and analysts, leading to potential stock movement.
The upcoming summit offers immediate exposure, which can influence trading behavior and stock interest soon after the event.
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12 – 13, 2025. The fireside chat is scheduled to take place on Wednesday, November 12, 2025, at 10:00 AM ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
